← All trials
NCT06273020
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 17, 2022
- Primary completion
- Nov 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Feb 22, 2024
- Last posted
- Feb 22, 2024
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Autonoma de Nuevo LeonLead sponsor
- Universidad Autonoma de Nuevo LeonOfficial
- Ever Neuro Pharma GmbHCollaborator
- Universidad Autonoma de Nuevo LeonSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.